The expanded collaboration builds on the recent joint development efforts of Acepodia and Biocytogen to evaluate selected bispecific antibody and dual-payload ADC programs.
Biocytogen Pharmaceuticals Co., Ltd. and Acepodia announced the execution of an option and license agreement that provides for a structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to advance the development of bispecific antibody-drug conjugate dual-load (BsAD2C) drugs.
Through this agreement, Acepodia secures the option to acquire an exclusive worldwide license from Biocytogen for two BsADC programs. According to the terms of the agreement, Biocytogen is entitled to an upfront option fee and, upon exercise of the option by Acepodia, to further payments: option exercise fees, development milestone payments, and regulatory, marketing, and royalty fees on future product sales. The financial terms of the agreement have not been disclosed.
“This new agreement builds on our recent development collaboration with Acepodia, which focused on evaluating and selecting leading bispecific antibodies and dual-payload ADCs,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Based on our preclinical research to date, we firmly believe that combining Biocytogen’s RenLite® platform with Acepodia’s AD2C technology represents a promising approach for developing next-generation, dual-payload bispecific ADCs.”
Also Read: Novotech Names Anand Tharmaratnam as New CEO
“The options-based framework gives us the opportunity to systematically examine how dual-load conjugation strategies can be applied to bispecific antibody formats,” said Dr. Sonny Hsiao, Chairman and CEO of Acepodia. “This collaboration demonstrates our commitment to a disciplined, data-driven expansion of the AD2C platform.”
The expanded partnership aims to leverage the complementary strengths of the platforms and develop next-generation ADC designs that can overcome certain limitations of traditional ADC programs. The joint team is approaching the milestones for candidate evaluation. Decisions regarding the next steps are based on current research findings as well as Acepodia’s internal governance and option exercise criteria.
Source: Businesswire